NTRK1 and hepatocellular carcinoma: Up to now, sorafenib, which inhibits multiple receptor tyrosine kinases (RTKs), especially VEGF-R2/3 (vascular endothelial growth factor-receptor), platelet-derived growth factor-β (PDGFR-β), and raf kinase, is the only useful chemotherapeutic agent in managing unresected HCC [4].